Skip to content

Study for the clinical efficacy of a vaginal gel in the treatment of female genital tract HPV infection and related diseases

Study for the clinical efficacy of a vaginal gel in the treatment of female genital tract HPV infection and related diseases

Status
Recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900028503
Enrollment
Unknown
Registered
2019-12-24
Start date
2019-12-10
Completion date
Unknown
Last updated
2020-01-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HPV infection

Interventions

Initial infection of HPV:vaginal gel
Persistent HPV infection:vaginal gel
Low intraepithelial neoplasia with HPV infection:vaginal gel

Sponsors

None listed

Eligibility

Sex/Gender
Female
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. aged from 18 to 70 years female; 2. Clinically diagnosed as HPV positive patients (including primary infection and persistent infection), or pathologically diagnosed as cervical low-grade intraepithelial neoplasia (CIN1) or vaginal low-grade intraepithelial neoplasia (VAIN1) with HPV infection.

Exclusion criteria

Exclusion criteria: 1. Allergic to any component in the product; 2. Cervical cancer or high-grade cervical/vaginal intraepithelial neoplasia has been confirmed by pathology; 3. Those who have taken measures to treat HPV infection in the past 3 months; 4. Long-term use of corticosteroids or immunosuppressants; 5. Pregnant or nursing women, or those who have a family planning in the near future; 6. The researcher considers that the study is not suitable for patients for other reasons.

Design outcomes

Primary

MeasureTime frame
HPV-DNA;

Countries

China

Contacts

Public ContactYin Lu

Nanjing University of Chinese Medicine

luyingreen@126.com+86 15605190001

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026